The pharmacokinetics and distribution of ticarcillin and clavulanic acid were studied in rats and rabbits after intravenous coadministration of the compounds. The elimination half-lives for ticarcillin and clavulanic acid were similar in both rats (ticarcillin, 0.22 h; clavulanic acid, 0.24 h) and rabbits (ticarcillin, 0.38 h; clavulanic acid, 0.31 h). Both compounds distributed widely throughout rat tissues, and the patterns of distribution were similar to those observed for other j3-lactams. Values for penetration into rat pleural, peritoneal, and subcutaneous fluids calculated from the equation (AUCfljd/AUC,.rum) x 100, where AUC is the area under the concentration-time curve, were between 83 and 93% for ticarcillin and 86 and 103% for clavulanic acid. Values for penetration into tissue cages in rabbits were 139% 45% for ticarcillin and 109% + 22% for clavulanic acid. The penetration of clavulanic acid into rabbit cerebrospinal fluid was higher (P < 0.05) (4.0% 0.61%) than that of ticarcillin (1.3% ± 0.53%). Overall, the results show that ticarcillin and clavulanic acid distribute readily throughout body tissues and fluids and predict that the penicillin and ,-lactamase inhibitor would be present together at sites of infection.
Ticarcillin is active against a broad range of gram-positive and -negative bacteria, including Pseudomonas aeruginosa. It shows moderate stability in the presence of the Richmond class I ,-lactamases but is inactivated by most other ,Blactamases encountered in clinical isolates. In the presence of the ,B-lactamase inhibitor clavulanic acid, however, the spectrum of activity is extended to include many bacterial strains resistant to ticarcillin alone (5, 7, 15) .
In the treatment of infections, the inhibitor should display distribution characteristics similar to ticarcillin to achieve effective concentrations of both compounds at infected sites.
In the experiments described here, the pharmacokinetics and distribution properties of ticarcillin and clavulanic acid were characterized after intravenous coadministration of the two compounds to rats and rabbits. The doses administered in the experiments were calculated on the basis of dose/ surface area (11) to be comparable with a recommended dose of ticarcillin-clavulanic acid for humans (3 g 50 ,ug/ml for ticarcillin and 0.08 to 5.0 ,ug/ml for clavulanic acid. The correlation coefficients for the regression lines of the standard solutions were not less than 0.997. The coefficients of variation for the assays were between 2.8 and 3.3% for ticarcillin and between 6.1 and 9.4% for clavulanic acid. Serum samples were assayed against standard solutions prepared in the appropriate animal serum. When dilutions were required to bring the expected concentrations within the concentration range of the assay, dilutions of the serum samples were nmade into phosphate-buffered saline and assayed against standards prepared in the appropriate dilution of serum. Rabbit tissue cage fluid was assayed against standards prepared in a 1 in 3 dilution of rabbit serum in phosphate-buffered saline. Standards prepared in phosphate-buffered saline were used to assay dilutions of tissue cage fluid, rabbit CSF, and rat pleural, peritoneal, and subcutaneous fluids. Tissue homogenate supernatants were assayed against standards prepared in Sorensen buffer (pH 6.5) because preliminary studies had indicated there was <10% difference between the assay results for the solutions prepared in the supernatants or the required dilutions of the supernatants and those prepared in buffer.
RESULTS
Pharmacokinetic studies. The concentrations of ticarcillin and clavulanic acid measured in rat and rabbit sera after coadministration are shown in Fig. 1 . In the rats, the concentrations of the two compounds declined in parallel and data were fitted to an open one-compartment model. In the rabbits, the concentrations of clavulanic acid declined monoexponentially and were fitted to an open one-compartment model, whereas ticarcillin concentrations declined biexponentially, and data were fitted to an open twocompartment model. The pharmacokinetic parameters are shown in Table 1 . In both animal species the elimination half-lives of ticarcillin and clavulanic acid were similar, but the values were higher in the rabbit. There were differences in the apparent volumes of distribution and clearance of the two compounds, with values for clavulanic acid generally higher than those for ticarcillin in both species.
Protein binding studies. Concentrations of clavulanic acid ranged from 1.8 of clavulanic acid to serum proteins in these samples was not dependent upon concentration, and means with standard deviations were therefore calculated. The binding of clavulanic acid in rabbits was 21.1% ± 4.4%. In rats, values ranged from 0 to 14.0% with a mean of 3.5%; a standard deviation was not calculated for these results because there was no binding in some samples. These values were similar to or lower than those observed previously for clavulanic acid in rats (13) . Concentrations of ticarcillin in rabbit serum samples taken at 10 and 60 min ranged from 20.7 to 830 ,ug/ml. The binding of ticarcillin was not dependent upon concentration, and the mean with standard deviation was 49.6% ± 1.4%. In rats, however, there was some evidence that protein binding was concentration dependent. The concentrations of ticarcillin in the 5-min samples were between 889 and 737 ,ug/ml, and binding ranged widely from 18.8 to 39.9%, whereas in the 45-and 90-min samples, concentrations were between 9.4 and 133 ,ug/ml and values for binding were generally slightly higher and more consistent, ranging from 35.1 to 45.1% (mean with standard deviation, 41.7% ± 3.4%).
Distribution in rat tissues. The ticarcillin and clavulanic acid concentrations in rat tissues are shown in Fig. 2 . The highest concentrations for both compounds were in the liver and kidneys. The concentrations of both compounds in the small intestine gradually increased over the 1-h period, whereas in other tissues, the concentrations tended to decline at rates similar to those in serum. Ticarcillin and clavulanic acid penetrated to a similar extent into tissues other than the small intestine and liver. For example, the concentrations of clavulanic acid in lungs over 1 h averaged 40% of those in serum, compared with 35% for ticarcillin, and concentrations of clavulanic acid in bone marrow averaged 56%, compared with 54% for ticarcillin. The percent penetration values in the remaining tissues ranged from 7 to 20% for clavulanic acid and from 5 to 18% for ticarcillin. Penetration into rat tissue fluids. The concentrations of ticarcillin and clavulanic acid in rat pleural, peritoneal, and subcutaneous fluids reached rapid equilibrium with those in serum (Fig. 3) . The areas under the concentration-time curves (AUCs) for ticarcillin in the fluids ranged between 83 and 93% of those in serum, values which were similar to those for clavulanic acid (86 to 103%).
Penetration into rabbit tissue cages. Both ticarcillin and clavulanic acid penetrated into subcutaneously implanted tissue cages (Fig. 4) . Concentrations in the tissue fluid retained within the cages were maintained considerably longer than in serum, and the compounds were detectable at 24 h after treatment. The peak concentrations of clavulanic acid in tissue cage fluid tended to occur slightly earlier than those of ticarcillin, but overall the extent of penetration, expressed as the (AUCfluid/AUCserum) X 100, was similar for the two compounds: 139% ± 45% for ticarcillin and 109% ± 22% for clavulanic acid.
Penetration into rabbit CSF. The concentrations of ticarcillin and clavulanic acid in rabbit serum and CSF are shown in Fig. 5 . The peak concentrations of both compounds in CSF occurred at 1 h after treatment, and levels were maintained longer than in serum. The elimination half-life for ticarcillin in CSF was 1.12 ± 0.1 h, compared with 0.52 ± 0.05 h in serum; for clavulanic acid the half-lives were 1.68 ± 0.46 h in CSF and 0.25 ± 0.05 h in serum. The extent of penetration of clavulanic acid was greater than for ticarcillin, and the AUC for clavulanic acid in CSF was 4.0% ± 0.61% of that in serum, compared with a value of 1.3% ± 0.53% for ticarcillin (P < 0.05; paired t test).
DISCUSSION
The pharmacokinetic experiments indicated that ticarcillin and clavulanic acid were eliminated more rapidly from rats than rabbits, but in each species the elimination half-lives of the compounds were similar, approximately 0.23 h in rats and 0.35 h in rabbits. The elimination half-lives of ticarcillin and clavulanic acid are also comparable in humans, although elimination is slower and the half-lives are about 1 h (3; t). Jackson, T. C. G. Tasker, D. Staniforth, R. Horton, A. T.
Murray, and A. Swaisland, Proc. 13th Int. Congr. Chemother., p. 55/43-55/45, 1983). The doses of ticarcillin and clavulanic acid used in the experiments reported here approximated, in terms of body surface area, a dose in humans of 3 g of ticarcillin with 100 mg of clavulanic acid. Body surface area is a function of body weight to the two-thirds power (6, 11) , and its use in adjusting doses may be regarded as a means to allow for species differences in physiology and metabolism. The influence of body size on pharmacokinetics is through its correlation with blood flow and clearance (12) , and pharmacokinetic parameters for a number of compounds including ,B-lactam antibiotics have been shown to correlate with body size (either body surface area or body weight) for a wide range of mammalian species including humans (4, 6, 11, 17) . By definition, the AUC is solely a function of clearance, and it is therefore of interest that the AUCs for ticarcillin and clavulanic acid in rat and rabbit sera approximated those observed in humans after a dose of 3 g of ticarcillin with 100 mg of clavulanic acid. Studies by Jackson et al. (8) found AUC values of 450 (294 to 580) ,ug. h/mI for ticarcillin and 8.3 (6.1 to 12.6) ,ug. h/ml for clavulanic acid. Similar results were observed by Bennett et al. (3) . These observations imply that dosing on the basis of body surface area indeed compensated for species differences in clearance of the two compounds.
The binding of ticarcillin and clavulanic acid to serum proteins in rats and rabbits was low to moderate and was similar to that observed in humans, 45% (16) and 22% (7), respectively. Although there were small differences between the binding of ticarcillin and clavulanic acid, the extent of binding would not be expected to significantly influence their distribution (2, 14) . The compounds readily penetrated subcutaneously implanted tissue cages in rabbits, and both compounds were detected in rat pleural, peritoneal, and subcutaneous fluids. On the basis of values calculated by expressing extravascular fluid AUC measurements as percentages of serum AUC measurements, the extent of penetration was similar for ticarcillin and clavulanic acid, suggesting comparable diffusion characteristics. The profiles of concentrations in tissue cage fluid for both compounds were consistent with the compact fibrous sheath surrounding the implant and the relatively large volume of fluid within 5000 r constituting a diffusional barrier to a rapid achievement of equilibrium between concentrations in the fluid and serum. In rat extravascular fluids, however, for which the surfacearea-to-volume ratio is large (18) , equilibrium was rapidly attained and concentrations in the fluids paralleled those in serum. These results suggest therefore that ticarcillin and clavulanic acid diffuse together into sites in the body for which the diffusional pathways can vary considerably in length. Small differences were apparent however in the penetration of the compounds into rabbit CSF, and clavulanic acid was seen to penetrate to a greater extent than ticarcillin.
The rat tissue distribution experiments showed that the pattern of distribution of ticarcillin and clavulanic acid was similar to that after administration of the two compounds in the ratio of 15:1 (10) and was not unlike that seen for other ,B-lactam compounds in rats (1) . The concentrations in tissues generally depended upon vascularity and whether excretory processes were present. It is thought that the lower levels of clavulanic acid in liver tissue were due to the biliary pathway being a minor route of elimination for this compound (9) .
The pharmacokinetic and distribution experiments reported here demonstrated that after coadministration, ticarcillin and clavulanic acid distribute widely throughout animal tissues and body fluids. Their pharmacokinetics were essentially compatible, and the results suggest that the penicillin and inhibitor would be present together at sites of infection.
